林裕誠醫師詳細介紹

國立台灣大學醫學院醫學系學士

國立台灣大學臨床醫學研究所醫學博士

-迄今臺北榮民總醫院兒童醫學部主治醫師

-迄今臺北榮民總醫院兒童胃腸科科主任

-迄今台灣小兒消化醫學會理事

-迄今中華民國肥胖研究學會理事

-迄今兒童肝膽疾病防治基金會董事

-迄今亞太APPSPGHAN科學委員會委員

-迄今台灣兒科醫學會研究委員會委員

-迄今台灣兒科醫學會兒科消化學委員會委員

-亞東紀念醫院小兒部主治醫師

-亞東紀念醫院醫療事務處處主任

-亞東紀念醫院小兒急診科科主任

-亞東紀念醫院共同研究室科主任

-科技部生科司婦幼醫學學門

兒童青少年肥胖症、脂肪肝

兒童青少年腸胃道疾病：嘔吐、腹瀉、腹痛、便秘、出血等

幼兒生長遲緩、嬰幼兒營養諮詢

兒童青少年肝膽疾病防治

腹部超音波、胃鏡、大腸鏡、肝纖維化掃描Fibroscan

兒科專科醫師

兒科消化學次專科醫師

肥胖症專科醫師

青少年醫學次專科醫師

消化系內視鏡專科醫師

Lin YC, Liao FM, Chao HC, Chen AC, Jeng YM, Lin CC, Tiao MM, Yang YJ, Yeung CY, Chen HL, Ni YH. Consensus statement on metabolic dysfunction-associated steatotic liver disease in children and adolescents from the joint TASL-TSPGHAN expert committee. JGH Open. [Accepted for publication].

Lin YC, Wu CC, Li YE, Chen CL, Lin CR, Ni YH. Full-length 16S rRNA sequencing reveals gut microbiome signatures predictive of MASLD in children with obesity. BMC Microbiol. 2025;25(1):146.

Lin YC, Liu PC, Chou FF, Hou IC, Chou CC, Chen CW, Hu SH, Chen SP, Lo HJ, Huang FF. Beliefs underlying weight control behaviors among adolescents and emerging adults living with obesity: an elicitation qualitative study. BMC Public Health. 2024;24(1):3292.

Chen CL, Huang FF, Lin HF, Wu CC, Ni YH, Lin YC. Tat-beclin-1 peptide ameliorates metabolic dysfunction-associated steatotic liver disease by enhancing hepatic autophagy. Int J Mol Sci. 2024;25(22):12372.

Chang PS, Chang PF, Lin YC. Usefulness of the triglyceride glucose index to predict nonalcoholic fatty liver disease in children with obesity. J Pediatr. 2023;255:260–261.

Liu PC, Lin YC, Gau BS, Tung HH, Hu SH, Chen CW. Association between lifestyle-related, psychosocial factors and obesity among female adolescents in Taiwan. J Pediatr Nurs. 2023;68:e58–e68.

Lin YC, Chang PF, Ni YH. Updated upper limits of normal serum alanine aminotransferase levels for screening metabolic dysfunction-associated fatty liver disease in obese children. J Formos Med Assoc. 2022;121:2548–2555.

Chen CL, Lin YC. Autophagy dysregulation in metabolic associated fatty liver disease: a new therapeutic target. Int J Mol Sci. 2022;23(17):10055.

Lin YC, Lin HF, Wu CC, Chen CL, Ni YH. Pathogenic effects of Desulfovibrio in the gut on fatty liver in diet-induced obese mice and children with obesity. J Gastroenterol. 2022;57:913–925.

Lin YC, Chang PF, Liu K, Chang MH, Ni YH. Predictors for incidence and remission of nonalcoholic fatty liver disease in obese children and adolescents. J Formos Med Assoc. 2022;121:36–42.

Lin YC, Wu CC, Ni YH. New perspectives on genetic prediction for pediatric metabolic associated fatty liver disease. Front Pediatr. 2020;8:603654.

Huang MJ, Lin YC, Liu K, Chang PF, Huang CS. Effects of variation status and enzyme activity for UDP-glucuronosyltransferase 1A1 gene on neonatal hyperbilirubinemia. Pediatr Neonatol. 2020;61(5):506–512.

Liu HH, Lin YC, Chung CS, Liu K, Chang YH, Yang CH, Chen Y, Ni YH, Chang PF. Integrated counts of carbohydrate-active protein domains as metabolic readouts to distinguish probiotic biology and human fecal metagenomes. Sci Rep. 2019;9(1):16836.

Lin YC, Chang PF, Chang MH, Ni YH. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children. Liver Int. 2018;38(7):1300–1307.

Chitturi S, Wong VW, Chan WK, et al. (incl. Lin YC). The Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 2: Management and special groups. J Gastroenterol Hepatol. 2018;33(1):86–98.

Wong VW, Chan WK, Chitturi S, et al. (incl. Lin YC). The Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70–85.

Lin YC, Ni YH. Reply to: “Title: The IRGM rs10065172 variant increases the risk for steatosis but not for liver damage progression in Italian obese children.” J Hepatol. 2017;67(3):655–656.

Lin YC, Chang PF, Lin HF, Liu K, Chang MH, Ni YH. Variants in the autophagy related gene IRGM confer susceptibility to nonalcoholic fatty liver disease by modulating lipophagy. J Hepatol. 2016;65(6):1209–1216.

Chang PF, Lin YC, Liu K, Yeh SJ, Ni YH. Heme oxygenase-1 gene promoter polymorphism and the risk of pediatric nonalcoholic fatty liver disease. Int J Obes. 2015;39(8):1236–1240.

Lin YC, Chang PF, Chang MH, Ni YH. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am J Clin Nutr. 2014;99(4):869–874.

Lin YC, Chang PF, Chang MH, Ni YH. A common variant in the peroxisome proliferator-activated receptor-γ coactivator-1α gene is associated with nonalcoholic fatty liver disease in obese children. Am J Clin Nutr. 2013;97(2):326–331.

Lin YC, Chang PF, Hu FC, Yang WS, Chang MH, Ni YH. A common variant in the PNPLA3 gene is a risk factor for nonalcoholic fatty liver disease in obese Taiwanese children. J Pediatr. 2011;158(5):740–744.

Lin YC, Chang PF, Yeh SJ, Liu K, Chen HC. Risk factors associated with liver steatosis in obese children and adolescents. Pediatr Neonatol. 2010;51(3):149–154.

Lin YC, Chang PF, Hu FC, Chang MH, Ni YH. Variants in the UGT1A1 gene and the risk of pediatric non-alcoholic fatty liver disease. Pediatrics. 2009;124(6):e1221–e1227